Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: David Lewis, Steven Kanner, Stanley Crooke, David Suhy


Arrowhead Research has named David Lewis as its new chief scientific officer.

Lewis most recently served as site head for the company's Madiscon, Wis., research and development facility, which Arrowhead acquired from Roche in 2011. Before that, he held various positions with Mirus Bio, which was acquired by Roche in 2007.

Arrowhead also said that Steven Kanner has joined the company as vice president of biology, taking over Lewis' former role. Previously, Kanner was vice president of discovery biology at Astek Pharmaceuticals.

Isis Pharmaceuticals announced that CEO and Chairman Stanley Crooke has been awarded the 2013 Director of the Year Award for Companies in Transition from the non-profit Corporate Directors Forum.

Bio-Matrix Scientific Group said that David Suhy has joined the scientific advisory board of its subsidiary Regen BioPharma.

Suhy is currently the vice president of research and development at Tacere Therapeutics, a subsidiary of Benitec Biopharma currently developing an expressed RNAi-based treatment for hepatitis C.

Regen recently took a license to Benitec's technology for use in developing a cancer vaccine.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.